These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36549931)

  • 1. Expanding the accessibility of harm reduction services in the United States: Measuring the impact of an automated harm reduction dispensing machine.
    Arendt D
    J Am Pharm Assoc (2003); 2023; 63(1):309-316. PubMed ID: 36549931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the impact of naloxone dispensation at public health vending machines in Clark County, Nevada.
    Allen ST; O'Rourke A; Johnson JA; Cheatom C; Zhang Y; Delise B; Watkins K; Reich K; Reich R; Lockett C
    Ann Med; 2022 Dec; 54(1):2692-2700. PubMed ID: 36168975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fentanyl harm reduction strategies among Latinx communities in the United States: a scoping review.
    Luna G; Dermid G; Unger JB
    Harm Reduct J; 2024 Aug; 21(1):150. PubMed ID: 39152433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responding to a surge in overdose deaths: perspectives from US syringe services programs.
    Frost MC; Austin EJ; Corcorran MA; Briggs ES; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Des Jarlais DC; Williams EC; Glick SN
    Harm Reduct J; 2022 Jul; 19(1):79. PubMed ID: 35854351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014.
    Wheeler E; Jones TS; Gilbert MK; Davidson PJ;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):631-5. PubMed ID: 26086633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overdose Education and Naloxone Distribution Within Syringe Service Programs - United States, 2019.
    Lambdin BH; Bluthenthal RN; Wenger LD; Wheeler E; Garner B; Lakosky P; Kral AH
    MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(33):1117-1121. PubMed ID: 32817603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organize and mobilize for implementation effectiveness to improve overdose education and naloxone distribution from syringe services programs: a randomized controlled trial.
    Lambdin BH; Bluthenthal RN; Garner BR; Wenger LD; Browne EN; Morris T; Ongais L; Megerian CE; Kral AH
    Implement Sci; 2024 Feb; 19(1):22. PubMed ID: 38419058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing peer recovery services for overdose prevention in Rhode Island: An examination of two outreach-based approaches.
    Waye KM; Goyer J; Dettor D; Mahoney L; Samuels EA; Yedinak JL; Marshall BDL
    Addict Behav; 2019 Feb; 89():85-91. PubMed ID: 30278306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accessing Take-Home Naloxone in British Columbia and the role of community pharmacies: Results from the analysis of administrative data.
    Moustaqim-Barrette A; Papamihali K; Mamdani Z; Williams S; Buxton JA
    PLoS One; 2020; 15(9):e0238618. PubMed ID: 32915834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An individual-based dynamic model to assess interventions to mitigate opioid overdose risk.
    Gallant K; Lukeman R
    Harm Reduct J; 2024 Aug; 21(1):146. PubMed ID: 39135022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing naloxone distribution to prevent opioid overdose fatalities: results from piloting the Systems Analysis and Improvement Approach within syringe service programs.
    Patel SV; Wenger LD; Kral AH; Sherr K; Wagner AD; Davidson PJ; Lambdin BH
    BMC Health Serv Res; 2023 Mar; 23(1):278. PubMed ID: 36949494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racialized environments and syringe services program implementation: County-level factors.
    Bluthenthal RN; Humphrey JL; Strack CN; Wenger LD; LaKosky P; Patel SV; Kral AH; Lambdin B
    Drug Alcohol Depend; 2024 Oct; 263():112430. PubMed ID: 39216198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community-based opioid overdose prevention programs providing naloxone - United States, 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Feb; 61(6):101-5. PubMed ID: 22337174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire.
    Bolivar D; Hartung D; Silcox J; Bratberg J; Boggis J; Rabin M; Green TC
    J Am Pharm Assoc (2003); 2023; 63(1):330-335.e1. PubMed ID: 36369076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating fentanyl test strips as a harm reduction strategy in rural and urban counties: study protocol for a randomized controlled trial.
    Short Mejia A; Smith GA; Fernandez SA; Freisthler B; Grella C; Michaels NL
    Trials; 2024 Sep; 25(1):587. PubMed ID: 39232778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States.
    Lambdin BH; Davis CS; Wheeler E; Tueller S; Kral AH
    Drug Alcohol Depend; 2018 Jul; 188():370-376. PubMed ID: 29776688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Opioid Epidemic in NC: Progress, Challenges, and Opportunities.
    Kansagra SM; Cohen MK
    N C Med J; 2018; 79(3):157-162. PubMed ID: 29735617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowering barriers to naloxone access through a student-led harm reduction program.
    Brown M; Tran C; Dadiomov D
    J Am Pharm Assoc (2003); 2023; 63(1):349-355. PubMed ID: 36443177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of a statewide community pharmacy approach to opioid harm reduction.
    Sexton SM; Marciniak MW; Gatton O; Shelton P
    J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.